

Gene Therapy for B-thalassemia; New Challenges

Maged MN¹, Mohamed MN², Lamia H. Shehata³

Mazahmiya Hospital¹, Ministry of Health, Kingdom of Saudi Arabia, Department of Ob/Gyn,
King Fahd Hospital², Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery,
Care National hospital³, Department of Radiology.

Corresponding Author: Maged MN

ABSTRACT

Recently, gene therapy clinical preliminaries have been effectively applied to hemoglobinopathies, for example, sickle cell disease (SCD) and β -thalassemia. Among the extraordinary disclosures that prompted the structure of genetic ways to deal with fix these disorders is the revelation of the β -globin locus control region and a few related transcription factors, which determine hemoglobin exchanging just as significant level, erythroid-specific expression of genes at the β -globin locus. Additionally, expanding proof shows that lentiviral vectors are proficient tools to embed large DNA components into nondividing hematopoietic stem cells, indicating consoling safe coordination profiles. On the other hand, genome altering could reestablish expression of fetal hemoglobin or target explicit mutations to restore expression of the wild-type β -globin gene. The latest clinical preliminaries for β -thalassemia and SCD are demonstrating promising results: patients had the option to stop transfusions or had diminished transfusion necessities. Be that as it may, toxic myeloablation and the significant expense of current ex vivo hematopoietic stem cell gene therapy stages speak to a barrier to a far reaching use of these methodologies. In this review, we sum up these gene therapy procedures and progressing clinical preliminaries. At last, we talk about potential systems to improve results, lessen myeloablative regimens and future difficulties to decrease the cost of gene therapy platform.

Keywords: gene therapy, β -thalassemia, hemoglobinopathy

INTRODUCTION

The thalassemias are genetically transmitted disorders. Ordinarily an individual acquires two β -globin genes found one each on two chromosomes 11, and two alpha globin genes one each on two chromosome 16, from each parent for example normal adult hemoglobin is $\alpha_2\beta_2$. Depending upon whether the hereditary defects or deletion lies in transmission of α or β globin chain quality, thalassemias are classified into α and β -thalassemias. Along these lines, quiet with α -thalassemias have basically ordinary alpha globin chain however their creation is debilitated. Additionally, persistent with beta thalassemias have basically ordinary alpha globin chain yet their creation are diminished. Every one of two main types of thalassemias may happen as heterozygous (minor) or homozygous state (major). The previous is commonly asymptomatic while the latter is severe congenital hemolytic anaemia.

Signs and Symptoms

Signs and symptoms of thalassemia rely upon the kind of thalassemia happened, for example contingent upon the sort of gene deletion or mutation. In spite of the fact that there are some common signs and symptoms of thalassemia which incorporates: serious tissue hypoxia, hemolytic anemia, marked hepatomegaly, marked erythroid hyperplasia, iron overload etc. (1)

Pathogenesis

In β -thalassemia, there is diminished pace of β -chain synthesis resulting in decreased synthesis of Hb A in the red cells. Pathogenesis of the β -thalassemia is more complex than that of α -thalassemia. As opposed to α -thalassemia, gene deletions once in a while ever cause β -thalassemia and is just found in an entity called hereditary persistence of fetal hemoglobin (HPFH). Rather, the majority of β -thalassemias emerge from various kinds of mutations of β -globin gene coming about because of single base changes. The symbol β^0 is utilized to demonstrate the total absence of synthesis while β^+ indicates incomplete amalgamation of β -globin chains. In excess of 100 such changes have been depicted influencing the favored sites in the coding sequences for example (in promotor area, termination region, splice junctions, exons, and introns).

A portion of the significant changes having impact on β -globin chain synthesis are as under:

A-Transcription defect: Mutation influencing transcriptional promotor sequence causing decreased synthesis of β -globin chain. Consequently the outcome is somewhat partially preserved synthesis i.e. β^+ thalassemia.

B-Translation deformity: Mutation in the coding arrangement causing stop codon (chain termination) interfering with β -globin messenger RNA. This would bring about no blend of β -globin chain and henceforth β^0 thalassemia.

C-mRNA splicing defects: Mutation prompts damaged mRNA that is degraded in the nucleus. Depending upon whether part of splice site stays unblemished or is completely corrupted, it might result in β^+ thalassemia or β^0 thalassemia.

B-thalassemia major:

It is the most extreme type of severe form of hemolytic anemia. There are further two sorts:

β^0 thalassemia major portrayed by complete nonattendance of β chain combination

β^+ thalassemia major having incomplete suppression of β chain synthesis.

β -Thalassemia intermedia:

It is β -thalassemia of intermediate degree of severity that does not require regular blood transfusions. These cases are genetically heterozygous (β^0/β or β^0/β^+).

Heterozygous form: β -Thalassemia minor (trait):

It is a mild asymptomatic condition in which there is moderate suppression of β -chain synthesis.

Current disease management of β -thalassemia comprises of:

Prenatal diagnosis

Transfusion treatment

Allogeneic bone marrow transplantation (BMT). (2-4)

Just the allogenic BMT is conceivably curative.(5) Consequently, a few places have used this approach as a definitive treatment, in spite of the fact that the graft-versus-host disease have a potential long – term complication of allogeneic hematopoietic stem cells (HSCs) transplantation.(6)

Moreover, accessibility of allogeneic bone marrow is restricted by finding an identical human leucocyte antigen (HLA) - matched bone marrow donor. Likewise, patients with severe β -thalassemia may benefit from new genetic and cellular approaches. From this planned, β -thalassemia is the excellent candidate disease for genetic based treatments in autologous HSCs. On the other hand, somatic cells reprogrammed to induce pluripotent stem cells may likewise give a potential new way to treat β -thalassemia. (7-8)

Gene therapy ordinarily includes the addition of a functioning gene into cells to correct a cellular function or to give another cell function.(9) diseases, for example, cystic fibrosis, combined immunodeficiency conditions, muscular dystrophy, hemophilia , gene therapy can be utilized to correct or replace the defective genes. (10-12)

Gene Therapy History

The main clinical examination utilizing gene transfer was reported. (13) Rosenberg and his colleagues utilized a retroviral vector to move the neomycin resistance marker gene into tumor-invading lymphocytes acquired from five patients with metastatic melanoma. These lymphocytes at that point were extended in vitro and later re-implanted into the particular patients. (14).

Vectors

Encouraging the transfer of genetic informations into a cell are vehicles basically called as vectors. Vectors can be isolated into viral and non-viral delivery systems. The most ordinarily utilized viral vectors are gotten from retrovirus, adenovirus and adeno-associated virus (AAV). Other viral vectors that have been less widely utilized are gotten from herpes simplex virus 1 (HSV-1), vaccinia virus, or baculo virus. Non-viral vectors can be either plasmid deoxyribonucleic acid (DNA), which is a circle of twofold abandoned DNA that imitates in bacteria or chemically synthesized compounds that are or look like oligodeoxynucleotides.

Viral Vectors

Retroviruses

A class of viruses that can make twofold abandoned DNA duplicates of their RNA genomes. These duplicates of its genome can be incorporated into the chromosomes of host cells. Human immunodeficiency infection (HIV) is a retrovirus e.g.- One of the issues of gene treatment utilizing retroviruses is that the integrate compound can embed the genetic material of the virus into any discretionary situation in the genome of the host; it haphazardly embeds the genetic material into a chromosome. In the event that genetic material happens to be embedded in the middle of one of the original genes of the host cell, this gene will be disturbed (insertional mutagenesis). In the event that the gene happens to be one controlling cell

division, uncontrolled cell division (i.e., malignancy) can happen. This issue has as of late been tended to by using zinc finger nucleases. (15)

Adenovirus (16)

To maintain a strategic distance from issue of embedding genes at wrong destinations, a few scientists have gone to different kinds of viruses. A class of virus with twofold stranded DNA genome that can cause respiratory, intestinal and eye infection. When these viruses infect a host cell, they bring their DNA particle into the host. The genetic material of the adenovirus isn't joined into the host cell's genetic material. The material of the adenovirus isn't fused into the host cell's genetic material. The DNA particle is left in the nucleus of the host cell, and the directions in this additional DNA molecule are interpreted. Adenovirus additionally can infect a more extensive assortment of cells than retrovirus, including cells that isolate all the more gradually, for example, lungs cells. Notwithstanding, adenovirus likewise are bound to be assaulted by the patient's immune system and the elevated levels of virus required for treatment regularly incite an unfortunate inflammatory reaction. Notwithstanding these disadvantages, this vector framework has been advanced for rewarding malignancy of liver and ovaries and surely the gene therapy treatment item to be licensed to treat head and neck disease is Gendicine, adenoviral product. (17)

Adeno-related viruses [AAVs]

One of the most encouraging potential vectors is an as of late found virus called the AAV, which infects an expansive scope of cells including both dividing and non-dividing cells. AAVs are from the Parvovirus family with a genome of single stranded DNA. It can embed genetic material at a particular site on chromosome 19 with close to 100% assurance. Many people convey AAV which don't cause disease and don't incite an immune reaction. It is currently being utilized in fundamental

investigations to treat genetic blood disease hemophilia, muscle and eye diseases. The central downside of AAV is that it is little, conveying just two genes. Its payload along these lines is moderately constrained. (18)

Herpes simplex infections (HSV)

A class of double- stranded DNA viruses that infect a specific cell type, neurons. Herpes simplex infection type 1 is a typical human pathogen that causes mouth blisters.

It is a human neurotropic infection, which is for the most part utilized for gene transfer in sensory system. It has a large genome contrasted with different viruses, which empower researcher to embed more than one therapeutic gene into a single virus, preparing for treatment of disorders brought about by more than one gene defect. HSV causes a perfect vector as it can contaminate a wide scope of tissues including muscle, liver, pancreas, and nerve and lung cells. The wild kind of HSV-1 infection can contaminate neurons which are not dismissed by immune system. (19)

Non-viral strategies

In correlation with infection inferred vectors, non-viral vectors have a few points of interest, for example, the wellbeing of organization without immunogenicity, practically boundless transgene size and the chance of repeated administration. (20) Non-viral quality conveyance frameworks by and large comprise of three classes: (a) stripped DNA conveyance, (b) lipid-based and (c) polymer-based delivery. (21)

Naked plasmid DNA

The least difficult strategy of non-viral gene transfer is the utilization of alleged stripped DNA. A progression of approaches for stripped plasmid DNA based quality conveyance procedures have been accounted for as of late like, naked plasmid DNA move strategy wherein a cytotoxic T-lymphocyte antigen 4-immunoglobulin (CTLA4-Ig) gene was conveyed utilizing an exposed plasmid DNA.(22) Naked DNA

was utilized for antiangiogenic treatment where the fetal liver kinase-1 gene was delivered.(23) One additionally fascinating territory that is the utilization of bare plasmid DNA gene conveyance as electro gene treatment which is done after infusion of naked plasmid DNA and conveyance of electric heartbeats straightforwardly to the tissue the statement of gene of intrigue can be obtained(24), in light of its inherent straightforwardness naked DNA is an attractive non-viral vector and also its simplicity of creation in bacteria and control utilizing standard recombinant DNA methods validates its utilization as non-viral gene transfer system. The other significant bit of leeway in utilizing naked DNA gene transfer system is its capacity to show almost no scattering and transfection at inaccessible destinations following conveyance and furthermore can be directed a few times as it doesn't show any antibody agent reaction against itself.[(25)

Cationic lipids

Cationic liposomes are a significant class of mixes reasonable for conveying contrarily charged DNA. Utilization of these reagents in vivo is tormented by their inalienable poison levels. Cationic lipids comprise of an emphatically charged head gathering, a hydrophobic tail and a linker interfacing the head to the tail gathering. The charged head bunches are generally quaternary amines, tails are immersed or unsaturated alkyl chains or cholesteryl gatherings. Cationic liposomes rather than impartial and anionic liposomes, which need DNA usage into the vehicle, cationic liposomes normally, make edifices with contrarily charged DNA. Their positive charge, besides, permits collaborations with the contrarily charged cell layer and therefore entrance into the cell is permitted. (26)

There are various reports on the utilization of different cationic lipids as non-viral gene conveyance vectors. (27) Cationic liposomes are utilized as of late is siRNA conveyance. siRNA complexed with

galactosylated cationic liposomes for liver parenchymal cell specific conveyance of siRNA has demonstrated that siRNA didn't experience nuclease processing and urinary discharge and additionally was conveyed proficiently to the liver and was identified in parenchymal cells as opposed to liver non parenchymal cells. The endogenous gene (ubc13 gene) expression in the liver was repressed up to 80% when edifices of ubc13-siRNA and galactosylated liposomes were controlled to mice. (28) Though cationic liposomes have been broadly utilized as transfection operators in vitro. There, in vivo achievement is tormented by harmfulness. It was discovered that the mechanism behind the harmfulness of cationic liposomes is to a great induction of apoptosis. A cDNA small scale exhibit study showed that up guideline of 45 genes identified with apoptosis, translation guideline and invulnerable reaction was expected to lipofection. (29)

Polymeric gene carriers

Polyplexes structure these polymers precipitously because of electrostatic connection between phosphate gatherings of DNA and oppositely charged gatherings of polycationic polymer. (30-32)

PEI (polyethylene mine) is progressively suitable as it has set a best quality level for non-viral gene transfer. Their capacity, to consolidate enormous DNA molecules and in the end prompting homogenous round particles of 100nm size or less as, they are fit for transfecting into cells proficiently for both in vitro and in vivo.(31) The other manufactured polymers indicating promising outcomes in gene transfer are poly-L-lysine. It is one of the primary polymers to be read for non-viral gene transfer in view of its peptidic nature i.e.it is biodegradable and henceforth it is increasingly appropriate for in vivo use. (33) Imidazole containing polymers have been accounted for to have productive transfection properties. - Amino gatherings of poly-Lysine were altered. In different methodologies with histidine or other

imidazole-containing structures end up being preferred transfecting specialists over the unmodified poly-L-lysine.(34-36) Transfection and cytotoxicity contemplates were carried on amino methacrylate polymer where quaternary amine bunches are associated with uncharged hydrophilic polymer of comparative structure which is poly (N-Hydroxypropyl methacrylamide)-b-poly(trimethylamino methylmethacrylate) (PHPMA-b-PTMAEM). It was discovered that while toxicity has not been changed a lot however the transfection proficiency has been expanded with the expansion of PHPMA block. (37)

Gene Therapy Technologies

The exchange of genetic material can be practiced in vivo through local or systemic inoculation or ex vivo where the objective of intrigue is gathered and altered outside of the life form before come back to the host. Move of manufactured DNA can be practiced by transduction or transfection. Such techniques for move incorporate either direct infusion of DNA into the beneficiary cells, or using strategies to actuate films saturation, receptor-intervened take-up or endocytosis. Transduction uses recombinant infection as a vector for gene transfer. Section of these vectors is interceded by cell-surface receptors. Concerns in regards to the immunogenicity of viral vector frameworks because of initiation of memory reactions against constituent viral proteins or an essential reaction to neoantigens has brought forth the advancement of engineered gene transfer frameworks which abuse transfection, the exchange of DNA by means of physical, substance or electrical methods.(38,39) Benefits of non-viral strategies for DNA move incorporate a decrease of dangers related with viruses (immune response, insertion mutagenesis) and restrictions to gene transfer, (for example, length of the transgene cassette).(40)

A-Physical Methods to Enhance Delivery 1-Electroporation

Electroporation is a strategy that utilizes short bursts of high voltage to convey DNA over the cell film. This is thought to cause brief arrangement of pores in the cell film, permitting DNA particles to go through. Electroporation is commonly effective and works over an expansive scope of cell types.

2. Gene Gun

In this method, DNA is covered with gold particles and stacked into a gadget which produces a power to accomplish entrance of DNA/gold into the cells.eg:- If the DNA is incorporated in an inappropriate spot in the genome, for instance in a tumor silencer gene, it could initiate a tumor. This has happened in clinical preliminaries for X-connected extreme consolidated immunodeficiency (X-SCID) patients, in which hematopoietic undifferentiated cells were transduced with a restorative transgene utilizing a retrovirus, and this prompted the advancement of T cell leukemia in 3 of 20 patients. (41)

3. Sonoporation

The procedure of acoustic cavitation is thought to disturb the cell layer and permit DNA to move into cells.

4. Magnetofection

In a strategy named magnetofection, DNA is complexed to an attractive particles and a magnet is put underneath the tissue culture dish to carry DNA edifices into contact with a cell monolayer.

B-Chemical Methods to Enhance Delivery

1. Oligonucleotides

The utilization of engineered oligonucleotides in gene therapy is to inactivate the genes engaged with the disease process. There are a few strategies by which this is accomplished. One system utilizes antisense specific to the objective gene to disrupt the transcription of the faulty gene. Another utilizes little particles of RNA called siRNA to flag the cell to

separate specific sequencies in the mRNA transcript of the faulty gene, upsetting interpretation of the defective mRNA and along these lines expression of the gene.

2. Lipoplexes and polyplexes

To improve the transfer of the new DNA into the cell, the DNA must be shielded from harm and (positively charged). At first, anionic and impartial lipids were utilized for the development of lipoplexes for manufactured vectors.

3. Dendrimers

A dendrimer is an exceptionally expanded macromolecule with a circular shape. The outside of the molecule might be functionalized from numerous points of view and a significant number of the properties of the subsequent build are dictated by its surface. Specifically it is conceivable to build a cationic dendrimer, for example one with a positive surface charges. When within the sight of genetic material, for example, DNA or RNA, charge complementarily prompts a brief relationship of the nucleic acid with the cationic dendrimer. On arriving at its goal the dendrimer-nucleic acid complex is then taken into the cell through endocytosis.

4. Hybrid strategies

To each strategy for gene transfer having weaknesses, there have been some mixture strategies built up that consolidate at least two procedures. Virosomes (42) are one model; they join liposomes with an inactivated HIV or influenza virus. This has been appeared to have increasingly productive gene transfer in respiratory epithelial cells than either popular or liposomal methods (43) alone. Different strategies include blending other viral vectors in with cationic lipids or hybridizing viruses.

C-Electrical techniques

Electro transfer is all the more entrenched. Applying an electrical field to cells adjusts the resting Trans membrane

potential, which can actuate porousness however the arrangement of reversible structural layer changes (electro pores). (44) Therapeutic degrees of gene expression have been accomplished, also the co moves of various plasmids. (45) Although more productive than synthetic or physical techniques, the effectiveness of electro move is still not as much as that seen with viral vectors.

The choice between transfection methodologies contrasted with transduction with a virus will generally rely upon the helpful objective. For transient gene expression or continue dosing situations, synthetic delivery systems envoy evident preferences. Alternately, adjustment of missing protein issue which requires long term, stable gene expression might be ideally serviced by viral vectors which can prompt combination of the transgene with have DNA and progressively stable constitutive protein expression. Synthetic delivery holds likely advantages in term terms of wellbeing, low recurrence of gene integration, capacity to present bigger segment of genes and simplicity of production. (46, 47) Another thought is the adequacy of expression: when all is said in done, viral vectors accomplish higher proficiency of expression than engineered systems. (48, 49) The improvement of artificial viral systems (synthetic viruses) stays a future methodology to bridle the upsides of viral and synthetic systems.

DISCUSSION

Beta-thalassemia are inherited anemia's that are brought about by the missing or lacking synthesis of the beta-hemoglobin chain and comprise the most widely recognized monogenic disease with 270 million heterozygotes worldwide.(50) The pervasiveness of beta-thalassemia was essentially favored in tropical and subtropical districts because of resistance against malaria acquired in the people conveying the pathological alleles. In any case, movements of populaces, just as usage of successful avoidance programs, have

changed the epidemiological guide for these syndromes. (51)

Without treatment, the extreme type of the disease, known as beta-thalassemia major or Cooley's iron deficiency, is lethal inside the principal decade of life.(52) The standard of care for these patients involves life-long transfusion treatment joined with pharmacological chelation to control iron accumulation(52,53) that impressively expands their future, if cautiously followed.(54) However, this profound established treatment contains an unnecessarily costly cash related load for some national economies and it truly deals an astonishing nature, customarily achieving treatment opposition and key organ sequelae.Indeed, explanation behind death in these patients, following blemished iron chelation, is cardiac failure due to secondaryhemochromatosis.(55) Older patients may be introduced to a higher risk of hepatocarcinoma.(56)

The standard curative treatment is allogeneic bone marrow transplantation from an organized related provider. Before long, basic burdens are connected with its execution, including compelled openness of noteworthy histocompatibility complex (MHC)- facilitated sponsors, the prerequisite for long stretch immunosuppression, confined application to the most young patients and extended peril of immunological disarrays, similarly as non-excusal mortality in increasingly settled subjects with organ damage.(57,58) This is in light of the fact that age-related extramedullary hematopoiesis, perpetual incapable erythropoiesis and iron assortment, may in reality inimically impact engraftment of the hematopoietic undifferentiated cell compartment. Also, transplants from elective providers, for instance, facilitated unimportant or haploidentical suppliers don't address a technique without complexities, since they are connected with by and large lower disease free perseverance and higher dreariness and mortality. (59, 60)

The goal of value treatment for the treatment of beta-thalassemia is to achieve stable introduction of helpful globin characteristics into the patient's own hematopoietic undifferentiated cells (HSCs) in order to address lacking erythropoiesis and hemolytic whiteness, as such thwarting the prerequisite for transfusion (61). This was predicted to offer a restorative potential to the people who couldn't encounter allogeneic transplantation or were deficient concerning a MHC-decent advocate, thusly avoiding the immunological risks of allogeneic hematopoietic fundamental microorganism transplantation (allo-HSCT) and without requiring safe camouflage to redirect them. Indeed, genetic treatment of beta-thalassemia has been early singled out as one of the most reassuring zones for future gene therapies. (62)

1: Safe Collection of Sufficient Numbers of HSCs

The soonest speculation towards a molecular treatment for beta-thalassemia was the *ex vivo* gene addition procedure: target cells with a repopulating limit, for instance, HSCs, are separated from the patient and co-refined with a viral vector passing on the therapeutic gene. These genetically modified cells are then reintroduced as a phenotypically functional graft into the patient from whom they were from the outset gathered and repopulate the bone marrow. To do all things considered, a preparative trim routine would be applied, in order to give enough niches for the engraftment of the gene modified cells over the uncorrected endogenous ones. (63)

It is settled that the genetically modified cells don't have a specific favored situation at the level of stem/early progenitor cells in beta-thalassemia patients.(64) Hence, colossal amounts of particularly engraftable transduced CD34+ cells, ought to be infused to achieve viable bone marrow reconstitution.(65) The prerequisite for gathering large amounts of HSCs from the patients is moreover fortified considering the way that a support of

unmodified CD34+ cells is also required, for salvage in the event of engraftment disappointment.

These days, fringe blood-prepared HSCs speak to the best hotspot for some autologous and allogeneic transplantation approaches.(66) This is on the grounds that this join source gives, under a minimal invasive procedure, higher quantities of HSCs contrasted with regular bone marrow harvest.(67) Plerixafor, a latest assembling operator, when utilized in mix with granulocyte-state invigorating variable (G-CSF), brings about quick preparation, inside hours following administration,(68) and displays a stamped synergism, subsequently expanding CD34+ cell yields by a few fold.(69)

As of not long ago, there was little data about the wellbeing and viability of activation in grown-up patients with beta-thalassemia. The eccentricity of HSC preparation with regards to beta-thalassemia generally lied on the broad extra medullary hematopoiesis that outcomes in splenomegaly, just as the hypercoagulability saw in these patients. Despite the fact that G-CSF is known to be commonly all around endured, the uncommon occasions of splenic rupture(70,71) or thrombosis(72) during preparation in ordinary givers or patients with hematologic malignancies raised worries for its wellbeing in thalassemia.

Preparative Conditioning

The idiosyncrasy of beta-thalassemia lies on the amazingly extended bone marrow that basically hampers powerful engraftment of gene remedied HSCs, which, significantly, give a specific preferred position just at the degree of erythroblasts and erythrocytes. (65) Hence, the genuinely fit for long term hematologic reconstitution hereditarily adjusted CD34+ cells, would need to be uncovered in especially serious specialty conditions upon transplantation.

Since beta-thalassemia is a non-malignant disease that requires total end of endogenous HSCs to present treatment, it

was at first discussed whether an incomplete or full myeloablation would give the ideal parity of sufficient vector-determined hematologic reconstitution, alongside the base conceivable peri-transplant morbidity and mortality. Supporters of the previous conclusion expressed that, to balance the low engraftment anticipated from in part myeloablative conditions, extremely enormous quantities of gene revised HSCs would need to be administered.(73) However, regardless of the empowering engraftment rates accomplished under serious states of a non-myeloablative setting in mouse models with different vectors,(74,75,76,77) it was before long found that this milder preparative routine couldn't be moved to the clinic.(78) Nowadays, a decreased force molding with Busulfan at 8 mg/kg is adequate to accomplish helpful engraftment of altered HSCs just for disorders that have a particular preferred position at the HSC level and don't have an extra medullary hematopoiesis background.(79,80)

Safety of Viral Vectors

The long route towards fruitful execution of gene therapy was not without entanglements and inconveniences. Leukemic change, likewise named insertional oncogenes is, in kids with X-SCID (81) or Wiskott-Aldrich syndrome (82) who was effectively rewarded by gamma-retroviral gene therapy, at first dominated the principal achievements of gene therapy and strengthened the examination towards the decrease of the genotoxicity danger of the system. Stresses were likewise raised from the kind, yet conceivably oncogenic predominant clone that developed in the main beta-thalassemia quiet at any point rewarded with gene therapy. (83)This was an aftereffect of the pair cHS4 component contained in the HPV569 vector, which was demonstrated, inclined to rework into a solitary cHS4 component upon vector insertion, (83, 84) and didn't secure against gene enactment

when set among enhancer and promotor areas.

These days, lentiviral vectors encoding human beta-globin those are as of now being utilized in clinical preliminaries, bear wellbeing highlights that ought to generously diminish the danger of vector-interceded oncogenesis contrasted with the early age gamma-retroviral vectors. Oneself inactivating (SIN) vector configuration including the cancellation of the viral enhancers in the vector LTR repeals these significant determinants of genotoxicity.(85) On the other hand, globin vectors contain an exceptionally incredible enhancer got from components of the LCR, and from the actuating intensity of this enhancer nature of the coordinating vectors should be protected.(86,87) likewise, genes communicated at ectopic locales, as in gene treatment applications, are exposed to the effect of the new chromosomal condition regularly bringing about differential expression and additionally silencing.(88)

Chromatin protectors are normally happening DNA components that help structure utilitarian limits between adjoining chromatin areas and have been proposed as a way to limit vector-intervened genotoxicity (enhancer-blocking covers) and breaking point transgene quieting (hindrance encasings). For a long time, the prototypic vertebrate cover remained the 1.2 kb cHS4, got from the DNAase easily affected site 4 of the chicken beta-globin locus control region.(88) However, the use of cHS4 in viral vectors for clinical state-of-the-art gene therapy has been related with a few confinements including imperfect titers, incomplete protection and deviant splicing.(83,88,89)

As of late, novel, little estimated protectors have been distinguished in the human genome by amazing genomic advancements, taking into consideration the investigation of epigenetic marks on a genome-wide level and understanding the setting in which gene guideline happens. Most of them show better enhancer-blocking movement than that of the cHS4

encasing and significantly lessen the genotoxicity chance in a viral-vector-intervened carcinogenesis mouse model. (90) Importantly, these covers are little estimated (<300 bp) and can be effectively suited in gene therapy vectors without detrimental effect affecting vector titers. Indeed, extensively described one of these components (named A1) and fused it into the TNS9.3.55 vector, building its protected adaptation, TNS9.3.55.A1, which is meant to be brought to the clinic. (78)

Beyond The Gene Addition Perspective

Gene editing, to be specific the in situ adjustment of genes by specific nucleases, speaks to a novel methodology which, inferable from the nuclease-related production of twofold abandoned breaks in the DNA, replacement, incorporation, or eradication of a course of action in a particular locus may get reachable. Such nucleases fuse zinc-finger nucleases (ZFNs), meganucleases (MNs), interpretation activator-like effector nucleases (TALENs), and the RNA-guided CRISPR/Cas9 structure (Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR-Associated Protein 9).(91)

To finish their ability, these nucleases rely upon unequivocal DNA joint effort modules and a nuclease zone. This framework is rendered conceivable either by homology-facilitated fix (HDR), or by non-homologous end-joining (NHEJ). Regardless of the way that the latter is more powerful than the past, NHEJ is bungle slanted and the consequence of DNA changes can't be controlled. On the other hand, HDR considers express, predestined changes to the goal sequence (92) and is consequently the perfect creating request for remunerating beta-thalassemia. (93)

Remaining Questions

Notwithstanding the inarguable accomplishment of value treatment in beta-thalassemic patients with non-b₀/b₀ genotypes, healing outcomes for patients with the b₀/b₀ genotype in spite of

everything stay flawed, thusly elevating the prerequisite for extra redesigns in globin vector design, gathering and execution. It is commonly perceived that gene balanced HSCs are slanted to choking of their repopulating limit because of ex vivo refined conditions. (65) Moreover, stable gene checking and convincing engraftment of value adjusted HSCs may be tried by the unpreventable cryopreservation of the conclusive outcome going before expansive gene attestation testing. (61) all together; these mediations may incite low engraftment levels post-transplant. Therefore, shows should be furthermore improved using an extent of various refinements, for instance, shortening the length of ex-vivo culture of HSCs, (94) progressing and transducing progressively primitive cells, (95) amending culture and cytokine centers to stimulate platelet and granulocyte recovery, (96) combining particles to expand (97, 98) or to transduce HSCs, ((99,102) and directing the balanced HSCs through elective routes to help engraftment and to decrease cell loss. (103)

Cationic included substances, for instance, which neutralize membrane charges and enhance the cell-virus interaction, are well-known for increasing transduction efficiency and are already used in clinical studies.(104) Other molecules, for instance, proteasome inhibitors,(105) cyclin-subordinate kinase p21,(106)or mTOR,(100) inhibit the post-entry managing from the plasma layer deeply, and may be clinically huge later on. Distinctive disturbs that help upkeep and advancement of HSCs join SR1 and UM729.(107,108) On the other hand, using little molecules to grow VCN may risk transduction of only a particular cell subset(109) and increase the threat of a prevalent clone rise.

A changed gathering process, using 2 minimal selective particles as transduction enhancers, (110) hopes to make higher VCN in vivo post quality treatment and is currently applied for the BB305 vector in the HGB-207 fundamental for thalassemic patients with non-b₀/b₀ genotypes. This

gives believe that such corrections may exhibit adequate to give transfusion freedom in the most testing accomplice of b0/b0 patients taking an interest in the HGB-212 preliminary.

Though no unfavorable occasions were so far saw in any of the clinical preliminaries led with the BB305, the TNS9.3.55, or the GLOBE vector, the requirement for higher transduction efficiencies so as to treat b0/b0 genotypes requires patients' nearby and long term reconnaissance, since a higher VCN in vivo may involve expanded danger of cell change. On the other hand, transducing cells at <1 VCN per cell and choosing just the gene changed HSCs from the complete cell population before mixture may lighten the requirement for higher VCNs in vivo, (109) just as forestall conceivable gene silencing. (111) However, this method is significantly longer in length, which may at last lead to lost engraftment potential and a lessening in clonal diversity.(112)

Gene editing systems by HDR, however they speak to a hypothetically sheltered and proficient approach to fix the patient's HSCs, do bear downsides. Such weaknesses incorporate low paces of HDR in HSCs because of peacefulness of this specific cell type,(113) wasteful transfer of nucleases to the cells,(114) potential off/oncotarget cleavage,(115) low engraftment capability of HSCs bearing fixed genes,(116) just as on track mutagenesis, for example, enormous cancellations and increasingly complex rearrangements.(117) what's more, since HDR is directed with an exogenously provided giver format, extremely huge number of HDR items would need to be produced and approved for human use so as to cover the >200 changes for beta-thalassemia,(110) except if just patients conveying the most widely recognized genotypes would be picked to be dealt with. The previously mentioned should be broadly assessed and tended to as this innovation is getting all the more generally received.

CONCLUSION

Most researchers accept the potential for gene therapy is the most energizing use of DNA science, yet attempted. How broadly this treatment will be applied, relies upon the improvement of system. As gene therapy is uprising in the field of medication, researchers accept that following 20 years, this will be the last fix of each hereditary disease. Genes may at last be utilized as medication and given as basic intravenous infusion of gene therapy vehicle that will look for our objective cells for stable, site-explicit chromosomal incorporation and resulting gene transfer, and since a draft of the human genome map is finished, research is concentrating on the capacity of every gene and the job of the defective gene play in infection. Gene therapy will eventually change our lives forever.

Conflict of interest

All authors declare no conflicts of interest.

Author's contribution

Authors have equally participated and shared every item of the work.

REFERENCES

1. Mohan H. The hematopoietic system. In: Mohan H, Mohan P, Mohan T, editors. The textbook of pathology. 5th Ed. New Delhi: Jaypee Brothers Medical Publishers; 2008. pp. 397–402
2. Giardini C, Lucarelli G. Bone marrow transplantation in the treatment of thalassemia. *Curr Opin Hematol.* 1994;1:170–6.
3. Burgess-Beusse B, Farrell C, Gaszner M, Litt M, Mutskov V, Recillas-Targa F, et al. The insulation of genes from external enhancers and silencing chromatin. *Proc Natl Acad Sci U S A.* 2002;99(Suppl 4):16433–7.
4. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, Kim HJ, et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. *Blood.* 2005;106:2530–3
5. Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. *Proc Natl Acad Sci U S A.* 2009;106:157–62.

6. Chin JY, Kuan JY, Lonkar PS, Krause DS, Seidman MM, Peterson KR, et al. Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. *Proc Natl Acad Sci U S A*. 2008;105:13514–9.
7. Dave UP, Akagi K, Tripathi R, Cleveland SM, Thompson MA, Yi M, et al. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. *PLoS Genet*. 2009;5:e1000491
8. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. *Proc Natl Acad Sci U S A*. 1993;90:8673–7.
9. Culver K. *Gene Therapy—A Handbook for Physicians*. Mary Ann Liebert, Inc., New York. 1994; 78-86.
10. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova J L, Bousso P, Deist F L and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. 2000; 288: 669-72.
11. Cavazzana-Calvo M, Hacein-Bey S, Yates F, de Villartay J P, Le Deist F and Fischer A. Gene therapy of severe combined immunodeficiencies. *J Gene Med*. 2001; 3: 201-206.
12. Cavazzana-Calvo M and Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? *J Clin Invest*. 2007; 117: 1456-65.
13. Rosenberg S A, Aebbersold P, Cornetta K., Kasid A, Morgan R A, Moen R, Karson E M, Lotze M T, Yang J C and Topalian S L. Gene transfer into humans- immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N Engl J Med*, 1990; 323: 570-78.
14. Edelstein M L, Abedi M R, Wixon J and Edelstein R M. Gene therapy clinical trials worldwide 1989-2004- an overview. *J Gene Med*. 2004; 6: 597-602.
15. Durai S, Mani M, Kandavelou K., Wu J, Porteus M.H, Chan-drasingaran S. *Nucleic Acids Res*. 2009; 33: 5978-5990.
16. Peng Z. Current status of Gene Therapy in China: Recombinant Human agent for treatment of Cancers. 2005; 16: 1016-1027.
17. Sibbald B. Death but one unintended consequence of gene therapy trial. *CMAJ*, 2001; 164: 1612.
18. AMT being able to produce AAV in adequate amounts (http://www.ots.at/presseaussendung/OTE_20080526_OTE0002).
19. Walther W and Stein U. Viral vector for gene transfer: a review of their use in the treatment of human disease. *Drug*. 2000; 60: 249-271.
20. Gardlik R, Palfy R, Hodosy J, Lukacs J, Turna J & Celec P. Vectors and delivery systems in gene therapy. *Med. Sci. Monit.*, 2005; 11(4): 110-121.
21. Par, T G, Jeong J H and Kim S W. Current status of polymeric gene delivery systems. *Adv Drug Del Rev*. 2006; 58: 467-486.
22. Yoshino H, Hashizume K and Kobayashi E. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. *Gene Ther*. 2006; 13: 1696-1702.
23. Yazawa H, Murakami T, Li HM, Back T, Kurosaka K and Suzuki Y. Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. *Cancer Gene Ther*. 2006; 13: 993-1001.
24. Cemazar M, Golzio M, Sersa G, Rols MP and Teissie J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? *Curr Pharm Des*. 2006; 12: 3817-3825.
25. Wolff JA and Budker V. The mechanism of naked DNA uptake and expression. *Adv Genet*. 2005; 54: 3-20.
26. Jafari M, Soltani M, Naahidi S, Karunaratne DN and Chen P. Nonviral approach for targeted nucleic acid delivery. *Curr med chem*. 2012; 19: 197- 208.
27. Nabel EG and Nabel GJ. Direct gene transfer: basic studies and human therapies. *Thromb Haemost*. 1993; 70: 202-203.
28. Sato A, Takagi M, Shimamoto A, Kawakami S and Hashida M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. *Biomaterials*. 2007; 28: 1434-1442.
29. Nguyen LT, Atobe K, Barichello JM, Ishida T and Kiwada H. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. *Biol Pharm Bull*. 2007; 30: 751-757.
30. Rolland A. Gene medicines: the end of the beginning? *Adv Drug Deliv Rev*. 2005; 57: 669-673.
31. Azzam T and Domb AJ. Current developments in gene transfection agents. *Curr Drug Deliv*. 2004; 1: 165-193.
32. Chesnoy S, Durand D, Doucet J and Couarraze G. Structural parameters involved in the permeation of propranolol HCl by

- iontophoresis and enhancers. *J Control Release*. 1999; 58: 163-75.
33. Wolfert MA, Dash PR, Nazarova O, Oupicky D, Seymour LW and Smart S. Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA. *Bioconjug Chem*. 1999; 10: 993-1004.
 34. Bennis JM, Choi JS, Mahato RI, Park JS and Kim SW. pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. *Bioconjug Chem*. 2000; 11: 637-645.
 35. Fajac I, Allo JC, Souil E, Merten M, Pichon C and Figarella Cl. Histidylated polylysine as a synthetic vector for gene transfer into immortalized cystic fibrosis airway surface and airway gland serous cells. *J Gene Med*. 2000; 2: 368-378.
 36. Midoux P and Monsigny M. Efficient gene transfer by histidylated polylysine/ pDNA complexes. *Bioconjug Chem*. 1999; 10: 406-411.
 37. Wolfert MA, Schacht EH, Toncheva V, Ulbrich K, Nazarova O and Seymour LW. Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers. *Hum Gene Ther*. 1996; 7: 2123-2133.
 38. Aihara H and Miyazaki J Gene transfer into muscle by electroporation in vivo. *Nat Biotechnol*. 1998; 16: 867-870.
 39. Mann MJ, Gibbons GH, Hutchinson H, Poston RS and Hoyt EG. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. *Proc Natl Acad Sci U SA*. 1999; 96: 6411-6416.
 40. Andre F and Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. *Gene Ther*. 2004; 11: S33-42.
 41. Wrobel I and Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. *Biochim. Biophys. Acta*. 1995; 1235: 296-304.
 42. Woods NB, Bottero V, Schmidt M, von Kalle C and Verma IM. Gene therapy: therapeutic gene causing lymphoma. *Nature*. 2006; 440: 7088.
 43. Wang Hongj W, Dmitry M, Leege T, Harkey M, Li Q, Thalia P, George S and Lieber A. A Capsid-Modified Helper-Dependent Adenovirus Vector Containing the β -Globin Locus Control Region Displays a Nonrandom Integration Pattern and Allows Stable, Erythroid-Specific Gene Expression *Journal of Virology*. 2005; 79(17): 10999-101.
 44. Andre F and Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. *Gene Ther*. 2004; 11: S33-42.
 45. Martel-Renoir D, Trochon-Joseph V, Galaup A, Bouquet C and Griscelli F. Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. *Mol Ther*, 2003; 8: 425-433.
 46. de Jong G, Telenius A, Vanderbyl S, Meitz A and Drayer J Efficient in-vitro transfer of a 60-Mb mammalian artificial chromosome into murine and hamster cells using cationic lipids and dendrimers. *Chromosome Res*. 2001; 9: 475-485.
 47. Schatzlein AG. Targeting of Synthetic Gene Delivery Systems. *J Biomed Biotechnol*. 2003; 149-158.
 48. Boeckle S and Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. *AAPS J*. 2006; 8: E731-742.
 49. Verma IM and Weitzman MD. Gene therapy: twenty-first century medicine. *Annu Rev Biochem*. 2005; 4: 711-738.
 50. Weatherall DJ. Thalassaemia: the long road from bedside to genome. *Nature Rev Genet*. 2004;5(8):625-631.
 51. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. *Bull World Health Organ*. 2008;86(6):480-487.
 52. Stamatoyannopoulos G, Nienhuis AW, Majerus P, Varmus H. *The Molecular Basis of Blood Diseases*. Philadelphia: WB Saunders; 2001.
 53. Weatherall DJ, Clegg J. *The Thalassemia Syndrome*. Oxford: Blackwell Scientific Publishers; 1981.
 54. Levine L, Levine M. Health care transition in thalassemia: pediatric to adult-oriented care. *Ann N Y Acad Sci*. 2010;1202(1):244-247.
 55. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematologica*. 2004;89(10):1187-1193.
 56. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. *Hemoglobin*. 2006;30(1):119-124.
 57. Gaziev D, Polchi P, Galimberti M, et al. Graft-versus-host disease after bone marrow

- transplantation for thalassemia: an analysis of incidence and risk factors. *Transplantation*. 1997;63(6):854–860.
58. Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. *Blood*. 1999;93(4):1164–1167.
 59. Gaziev D, Galimberti M, Lucarelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. *Bone Marrow Transplant*. 2000;25(8):815–821.
 60. La Nasa G, Caocci G, Argioli F, et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. *Bone Marrow Transplant*. 2005;36(11):971–975.
 61. Karponi G, Papayanni PG, Zervou F, Bouinta A, Anagnostopoulos A, Yannaki E. The functional effect of repeated cryopreservation on transduced CD34+ cells from patients with thalassemia. *Hum Gene Ther Methods*. 2018;29(5):220–227.
 62. Weatherall DJ, Clegg JB. Genetic disorders of hemoglobin. *Semin Hematol*. 1999;36(4 Suppl 7):24–37.
 63. Karponi G, Zogas N, Domvri K, et al. Prospects of gene therapy for pulmonary diseases: progress and limitations. *Med Chem*. 2017;13(4):308–318.
 64. Sadelain M, Rivière I, Wang X, et al. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. *Ann N Y Acad Sci*. 2010;1202(1):52–58.
 65. Psatha N, Karponi G, Yannaki E. Optimizing autologous cell grafts to improve stem cell gene therapy. *Exp Hematol*. 2016;44(7):528–539. doi:10.1016/j.exphem.2016.04.007
 66. Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. *Bone Marrow Transplant*. 2007;40(1):19–27.
 67. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. *Blood*. 1997;89(7):2233–2258.
 68. Broxmeyer HE, Orschell CM, Clapp DW. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J Exp Med*. 2005;201(8):1307–1318.
 69. Nademanee AP, DiPersio JF, Maziarz RT, et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34+ cell count: results of a subset analysis of a randomized trial. *Biol Blood Marrow Transplant*. 2012;18(10):1564–1572.
 70. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. *Lancet*. 1999;33(9152):555.
 71. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. *Transfusion*. 2004;44(8):1260–1261.
 72. Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). *Eur J Cancer*. 1993;29A(16):2338–2339.
 73. Yannaki E, Karponi G. Current status and developments in gene therapy for thalassemia and sickle cell disease. *Thalass Rep*. 2014;4(3):75–80.
 74. Boulad F, Wang X, Qu J, et al. Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. *Blood*. 2014;123(10):1483–1486.
 75. Karponi G, Psatha N, Lederer CW, et al. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. *Blood*. 2015;126(5):616–619.
 76. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. *Proc Natl Acad Sci U S A*. 2008;105(30):10547–10552.
 77. Miccio A, Poletti V, Tiboni F, et al. The GATA1-HS2 enhancer allows persistent and position-independent expression of a beta-globin transgene. *PLoS One*. 2011;6(12):e27955.
 78. Mansilla-Soto J, Riviere I, Boulad F, et al. Cell and gene therapy for the beta-thalassemias: advances and prospects. *Hum Gene Ther*. 2016;27(4):295–304.
 79. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. *Nat Med*. 2006;12(4):401–409.
 80. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with

- monosomy 7 consequent to EVII activation after gene therapy for chronic granulomatous disease. *Nat Med.* 2010;16(2):198–204.
81. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. *J Clin Invest.* 2008; 118(9):3143–3150.
 82. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. *Sci Transl Med.* 2014;6(227):227ra33.
 83. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. *Nature.* 2010;467(7313):318–322.
 84. Ronen K, Negre O, Roth S, et al. Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat beta-thalassemia. *Mol Ther.* 2011;19(7):1273–1286.
 85. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. *J Clin Invest.* 2009; 119(4):964–975.
 86. Hargrove PW, Kepes S, Hanawa H, et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. *Mol Ther.* 2008;16(3):525–533.
 87. Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. *PLoS One.* 2009;4(9):e6995.
 88. Emery DW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. *Hum Gene Ther.* 2011;22(6):761–774.
 89. Negre O, Bartholomae C, Beuzard Y, et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. *Curr Gene Ther.* 2015;15(1):64–81.
 90. Liu M, Maurano MT, Wang H, et al. Genomic discovery of potent chromatin insulators for human gene therapy. *Nat Biotechnol.* 2015;33(2):198–203
 91. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. *Nat Rev Genet.* 2014;15(5):321–334.
 92. Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the double-strand break. *Trends Cell Biol.* 2016;26(1):52–64.
 93. Cornu TI, Mussolino C, Cathomen T. Refining strategies to translate genome editing to the clinic. *Nat Med.* 2017;23(4):415–423.
 94. Larochelle A, Gillette JM, Desmond R, et al. Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. *Blood.* 2012;119(8):1848–1855.
 95. Masiuk KE, Brown D, Laborada J, Hollis RP, Urbinati F, Kohn DB. Improving gene therapy efficiency through the enrichment of human hematopoietic stem cells. *Mol Ther.* 2017;25(9):2163–2175. doi:10.1016/j.ymthe.2016.10.004
 96. Miller PH, Knapp DJHF, Beer PA, et al. Early production of human neutrophils and platelets posttransplant is severely compromised by growth factor exposure. *Exp Hematol.* 2016;44(7):635–640.
 97. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science.* 2010;329(5997):1345–1348. doi:10.1126/science.1191536
 98. Fares I, Chagraoui J, Gareau Y, et al. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. *Science.* 2014;345(6203):1509–1512.
 99. Fenard D, Ingraio D, Seye A, et al. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. *Mol Ther Nucleic Acids.* 2013;2:e90.
 100. Wang CX, Sather BD, Wang X, et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. *Blood.* 2014; 124(6):913–923.
 101. Heffner GC, Bonner M, Christiansen L, et al. Prostaglandin E 2 increases lentiviral vector transduction efficiency of adult human hematopoietic stem and progenitor cells. *Mol Ther.* 2018;26(1):320–328.
 102. Masiuk KE, Zhang R, Osborne K, Hollis RP, Campo-Fernandez B, Kohn DB. PGE2 and poloxamer synergetic F108 enhance transduction of human HSPCs with a β -globin lentiviral vector. *Mol Ther Methods Clin Dev.* 2019;13:390–398.
 103. Markt S, Scaramuzza S, Cicalese MP, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients

- affected by transfusion-dependent beta-thalassemia. *Nat Med*. 2019;25(2):234–241.
104. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. *N Engl J Med*. 2017;376(9):848–855. doi:10.1056/NEJMoa1609677
105. De Sio FR, Cascio P, Zingale A, Gasparini M, Naldini L. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. *Blood*. 2006;107(11):4257–4265.
106. Zhang J, Attar E, Cohen K, Crumpacker C, Scadden D. Silencing p21Waf1/Cip1/Sdi1 expression increases gene transduction efficiency in primitive human hematopoietic
107. Genovese P, Schirotti G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. *Nature*. 2014;510(7504):235–240.
108. Adair JE, Waters T, Haworth KG, et al. Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. *Nat Commun*. 2016;7:13173.
109. Bhukhai K, de Dreuzy E, Giorgi M, et al. Ex vivo selection of transduced hematopoietic stem cells for gene therapy of beta-hemoglobinopathies. *Mol Ther*. 2018; 26(2):480–495.
110. Sii-Felice K, Giorgi M, Leboulch P, et al. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice. *Exp Hematol*. 2018;64:12–32.
111. Kalberer CP, Pawliuk R, Imren S, et al. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice. *Proc Natl Acad Sci*. 2000;97(10):5411–5415.
112. Kennedy DR, McLellan K, Moore PF, Henthorn PS, Felsburg PJ. Effect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation. *Biol Blood Marrow Transplant*. 2009;15(6):662–670.
113. Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat Biotechnol*. 2015;33(5):538–542.
114. Zuris JA, Thompson DB, Shu Y, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. *Nat Biotechnol*. 2015;33(1):73–80.
115. Hendel A, Kildebeck EJ, Fine EJ, et al. Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. *Cell Rep*. 2014;7(1):293–305.
116. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. *Blood*. 2015;125(17):2597–2604.
117. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-cas9 leads to large deletions and complex rearrangements. *Nat Biotechnol*. 2018;36(8):765–771.

How to cite this article: Maged MN, Mohamed MN, Shehata LH. Gene therapy for B-thalassemia; new challenges. *International Journal of Science & Healthcare Research*. 2020; 5(3): 158-173.
